# A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

> **NCT07199452** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MK-4646
- **DRUG:** Rifabutin

## Key facts

- **NCT ID:** NCT07199452
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-10-28
- **Primary completion:** 2025-12-27
- **Final completion:** 2026-01-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07199452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07199452, "A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07199452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*